# Overview

Investigators, research staff, students and the Human Subject Research program (IRB), and the University share responsibility for the ethical conduct of human subjects research and for compliance with federal regulations, applicable state and local laws, and university policy.

# 2. Definitions

**Noncompliance:**  Failure (intentional or unintentional) to comply with applicable federal regulations, state or local laws, the requirements or determinations of the IRB, or university policy regarding research involving human subjects. Noncompliance can result from action or omission. Noncompliance may be non-serious (minor) or serious and may also be continuing (see below).

**Non-serious or minor noncompliance:** Noncompliance that does not increase risk to research participants, compromise participants’ rights or welfare, or affect the integrity of the research/data or the human research protection program. Examples of minor noncompliance may include but are not limited to the following: lapses in continuing IRB approval, minor changes in or deviations from an approved protocol, or administrative errors.

**Serious noncompliance:** Noncompliance that increases risk to research participants, compromises participants’ rights or welfare, or affects the integrity of the research/data or the human research protection program. Examples of serious noncompliance may include, but are not limited to the following: conducting or continuing non-exempt human subjects research without IRB approval; lack of legally effective informed consent from research participants; failure to report or review serious adverse events, unanticipated problems, or substantive changes in research; or inappropriate oversight of the research to ensure the safety of human subjects and the integrity of the research/data.

**Continuing noncompliance:** Noncompliance (serious or non-serious) that has been previously reported, or a pattern of ongoing activities that indicate a lack of understanding of human subjects protection requirements that may affect research participants or the validity of the research and suggest the potential for future noncompliance without intervention. Examples of continuing noncompliance may include, but are not limited to the following: repeated failures to provide or review progress reports resulting in lapses of IRB approval, inadequate oversight of ongoing research, or failure to respond to or resolve previous allegations or findings of noncompliance.

**Allegation of noncompliance:** An unconfirmed report of noncompliance.

**Finding of noncompliance:** An occurrence or determination of noncompliance that does not require further confirmation or investigation (e.g., failure to respond to the IRB within established deadlines, allegation of noncompliance determined by the IRB to be true).

# 3. General Principles

**Responsibility to Report:** The Center for Health Sciences expects all faculty, staff, students, and volunteers, acting in good faith, to report suspected or actual wrongful conduct associated with human subjects research.

**Cooperation with Proceedings:** Research will cooperation with the IRB and other institutional officials in review and investigation of allegations.

**Confidentiality:** Out of respect for all persons involved, all persons involved should strive to maintain confidentiality and discussion with individuals/sharing of information should be limited to the minimum necessary in order to adequately investigate.

# Evaluating Allegations of Noncompliance

Allegations of noncompliance should be forwarded to the Human Subject Research staff, who will process all allegations and findings of noncompliance, whether these reports arise internally (e.g., from faculty, staff, students, IRB staff, IRB members, or investigator self-reports) or from outside the university (e.g., research participants or regulators). Allegations of noncompliance will remain confidential to the extent permitted by Oklahoma law, consistent with the need to conduct an adequate investigation. The university will take reasonable steps to protect persons who file reports in good faith from retaliatory actions based on such filing, in accordance with state law and the Non-Retaliation Policy set forth by the Board of Regents for the Oklahoma Agricultural & Mechanical Colleges.

Actions undertaken in response to an allegation or finding of noncompliance will be completed in a timely manner, based on the circumstances and seriousness of the potential noncompliance. Under federal regulations, the IRB has the authority to suspend or terminate approval of research that is not being conducted in accordance with the IRB's requirements or that has been associated with unexpected serious harm to subjects. The IRB Chair or Vice-Chair, IRB Investigative Subcommittee, or IRB may suspend or terminate approval of an investigator’s research and/or secure critical documents at any time during or following an inquiry or investigation if necessary to assure the protection of research participants. The Office of Research will assure that the necessary resources are available to conduct a thorough review of all noncompliance.

# A. Initial Inquiry

1. IRB staff will consult with the Chair or Vice-Chair of the IRB responsible for reviewing the research, and as necessary university counsel, on all allegations or findings of noncompliance. Any individual with a potential conflict of interest may not participate in the initial inquiry. The Principal Investigator (PI) and co-investigator(s), as applicable, may be informed of an allegation of noncompliance or contacted for a response during the initial inquiry.

*Note: Minor noncompliance determinations may be made during expedited IRB review; however, serious and/or continuing noncompliance allegations identified during expedited IRB review will be forwarded to the IRB Chair or Vice-Chair for further consideration.*

1. If the investigator(s) is contacted for a request for information, a written response will be requested.

1. Possible outcomes of the initial inquiry include:
   * Dismissal of the allegation (i.e., unsubstantiated)
     + No further action required (i.e., for minor violations)
   * Further investigation required (i.e., when the results of the initial inquiry indicate that additional fact-finding is required to assess the alleged or reported noncompliance).
   * Corrective action(s) recommended (i.e., for minor violations)
   * Referral to the IRB Investigative Subcommittee (see B.2.)
   * Review by convened IRB required (i.e., noncompliance may be serious and/or continuing but further investigation is not needed)
   * Referral to other appropriate university process (e.g., misconduct review)
2. Initial inquiries will be completed promptly; however, the timing is dependent on the finding of noncompliance and on the nature of the potential noncompliance.

# B. Investigation and Investigative Subcommittee

1. The IRB Chair may request that additional fact-finding be conducted by IRB staff based upon the results of the initial inquiry and the nature of the potential noncompliance.

1. The IRB Chair may also request that an Investigative Subcommittee of the IRB be formed to further investigate allegations or reports of noncompliance. The Chair or Vice-Chair of the IRB responsible for reviewing the research will chair the investigation, members or alternates of the IRB will comprise the Subcommittee. The Subcommittee will be assisted by IRB staff and advised by university counsel as necessary. Any individual with a potential conflict of interest may not participate in the investigation. At least one IRB member should possess expertise appropriate for review of the potential noncompliance; additional IRB members or external consultants may also be included as determined necessary by the subcommittee Chair. The Investigative

Subcommittee will meet as necessary to ensure timely review of pending allegations.

1. The Investigative Subcommittee will consider materials and recommendations from the initial inquiry, the investigator(s)’ response, and other information relevant to the investigation (e.g., interviews, audit reports, literature searches, etc.). A summary report that includes the allegation, information considered by the Investigative Subcommittee, and its conclusions and recommendations will be prepared.
2. The investigator(s) will be informed in writing of the allegation and any further investigation. A written response may be requested, depending on the nature of the potential noncompliance, to facilitate review and conclusion of the investigation. The PI, research staff, or others may be interviewed and/or an audit of the investigator(s)’ research may be conducted during the investigation, as necessary.

1. Possible outcomes of the investigation as determined by the Chair, Vice-Chair, or IRB Investigative Subcommittee include:
   * Dismissal of the allegation (i.e., unsubstantiated)
   * No further action required (i.e., for minor violations)
   * Corrective action(s) required (i.e., minor violations)
   * Review by convened IRB required (i.e., noncompliance is considered to be serious and/or continuing).
   * Referral to other appropriate university process (e.g., misconduct review)

1. When review by the convened IRB is not warranted (e.g., dismissal of the allegation or minor violations), the investigator(s) will be notified in writing of the results of the investigation and required corrective actions, as applicable. The Institutional Official, investigator(s)’ Dean, Department Chair (or equivalent), and/or research

collaborators may also be informed, at the discretion of the Chair of the Investigative Subcommittee. Notification will be sent to the person(s) originating the report of noncompliance within 30 days, as applicable. Suspended IRB approval may be reinstated, as appropriate, based on the determinations of the Investigative Subcommittee and the response of the investigator(s). Reinstatement of IRB approval(s) will be reported by IRB staff within 30 days of the action to those previously informed of the suspension (i.e., Institutional Official, OHRP, any other sponsoring federal department or agency, etc.) and others (e.g., Office of Sponsored Programs), as necessary.

1. When the Investigative Subcommittee believes that serious and/or continuing noncompliance has occurred, the subcommittee’s summary report will be forwarded to the investigator(s) and the IRB members who were responsible for reviewing the research. The PI and co-investigator(s), as applicable, will be asked to respond to the subcommittee’s findings in writing, with a response deadline. The investigator(s) may also respond in person to the IRB at the convened meeting during which the noncompliance review will take place, to be scheduled following the receipt of the investigator(s)’ response. A personal advisor, whether faculty member or otherwise, may accompany the investigator(s), but the advisor may not participate in the discussion.

# C. Convened IRB Review

1. If a convened IRB meeting is determined to be necessary, the IRB members responsible for reviewing the research will review allegations or findings of noncompliance following initial inquiry or further investigation. The IRB will consider the information from the initial inquiry, further investigations, summary report from the Investigative Subcommittee (if any), the investigator(s)’ response (if any), and any other relevant materials (e.g., research protocol, consent form, etc.) to assess the seriousness of the potential noncompliance and to consider possible corrective action(s). The primary reviewer will lead discussion; materials as described above will be distributed to all scheduled attendees in advance of the meeting. The IRB will make final determinations in closed session by majority vote of a quorum of the members/alternates at the convened meeting.

1. The investigator(s) will be notified in writing of the final decision of the IRB. Notification will also be sent to the person(s) originating the report of noncompliance within 30 days, as applicable. If not previously reported, any suspension or termination of IRB approval or noncompliance that is determined to be serious or continuing will be reported by IRB staff (see below).

# 4. Corrective Actions

1. Corrective action(s) will be based on the nature of the noncompliance, degree to which research participants were placed at risk, occurrence of previous noncompliance, etc. The range of possible corrective actions that the Chair, Vice-Chair, IRB Investigative Subcommittee, or IRB may consider includes, but is not limited to the following:
   * Modification(s) of the research protocol or procedures
   * Modification(s) of the consent process or consent form
   * Providing additional information to current research participants (required when such information may relate to their willingness to continue in the research)
   * Providing additional information to past research participants
   * Reconfirming consent of current research participants
   * Requiring additional follow-up/monitoring for current and/or past research participants
   * Monitoring of the research (including audits) or consent process
   * Education or mentoring for the principal investigator and/or research staff
   * Additional reporting, including modifications of the continuing review schedule
   * Requiring additional resources to support the investigator’s research activities
   * Placing limitations (e.g., restriction to co-investigator status) on the investigator’s research activities or use of research data
   * Suspension of IRB approval for one or more of the investigator(s)’ studies
   * Termination of IRB approval for one or more of the investigator(s)’ studies.

1. The Chair or Vice-Chair of the IRB responsible for reviewing the research, Investigative Subcommittee, or convened IRB may review the investigator(s)’ response to corrective actions. If the PI and co-investigator(s), as applicable, do not comply with the required corrective action(s) within the time specified in the corrective action plan, additional action may be required, including suspension or termination of IRB approval(s) for ongoing human subjects research activities. The investigator(s) will be notified of resolution of corrective actions or the need for additional action(s). If not previously reported, any suspension or termination of IRB approval will be reported by IRB staff.

# 5. Investigator Appeals

As required by regulations, any decision of the IRB with respect to research involving human subjects is final. However, the convened IRB may review an investigator’s request for reconsideration or appeal to a determination regarding noncompliance and/or corrective actions as warranted by the presentation of new information or unusual circumstances. All investigator petitions must be made within 30 days of his/her notification of the IRB’s findings. The IRB will review an investigator’s request or appeal within 30 days, and the investigator will be notified in writing of the IRB’s decision within 14 days of the review.

# 6. Reporting

Noncompliance determined to be serious and/or continuing or any suspension or termination of IRB approval will be reported by IRB staff within 30 days of the finding to the investigator(s), IRB, Institutional Official, investigator(s)’ Dean and Department Chair (or equivalent), research collaborators, OHRP (for non-exempt category studies), FDA (as applicable for FDA-regulated research), any other sponsoring federal department or agency, and others (e.g., Office of Sponsored Programs) as necessary, in accordance with the University’s Federalwide Assurance.

# 7. Record Retention

Records relating to review and investigation of noncompliance will be retained by The Office of Responsible Research Practices for a minimum of three years after completion of the research or any corrective actions (whichever is longer), in keeping federal regulation, applicable state and local law, and university policy.

# 8. Applicable Regulations/Guidance

21 CFR 50.25(b)(5), 21 CFR 56.108(b)(2), 21 CFR 56.112, 21 CFR 56.113, 21 CFR

56.115(b), 45 CFR 46.103(b)(5)(i), 45 CFR 46.111(b)(5), 45 CFR 46.112, 45 CFR 46.113,

45 CFR 46.115(b), “Guidance on Reporting Incidents to OHRP” (06/20/11),